DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Kampmann Melissa S.

Kampmann Melissa S. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 13.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,785 shares of the medical device company's stock after purchasing an additional 4,450 shares during the period. DexCom accounts for 2.0% of Kampmann Melissa S.'s portfolio, making the stock its 27th largest position. Kampmann Melissa S.'s holdings in DexCom were worth $2,580,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Proficio Capital Partners LLC purchased a new position in DexCom in the fourth quarter worth about $5,812,000. SBI Securities Co. Ltd. bought a new position in DexCom in the 4th quarter worth approximately $49,000. Farther Finance Advisors LLC grew its stake in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock valued at $209,000 after acquiring an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC grew its position in shares of DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock valued at $357,000 after purchasing an additional 1,333 shares in the last quarter. Finally, Stonebridge Financial Group LLC increased its stake in DexCom by 944.5% in the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock worth $220,000 after acquiring an additional 2,909 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Sadie Stern sold 6,184 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president owned 109,621 shares in the company, valued at approximately $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. Insiders own 0.32% of the company's stock.

DexCom Stock Down 1.2%

DexCom stock traded down $0.98 during mid-day trading on Thursday, reaching $82.61. 1,840,773 shares of the company were exchanged, compared to its average volume of 4,388,817. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market cap of $32.39 billion, a P/E ratio of 61.65, a PEG ratio of 1.78 and a beta of 1.44. The business has a fifty day moving average of $82.80 and a 200 day moving average of $79.71. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company earned $0.32 earnings per share. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the subject of several research reports. Citigroup reiterated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Piper Sandler dropped their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Barclays lifted their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.